Endoscopic eradication therapy is effective for treating low-risk T1b esophageal adenocarcinoma, but high-risk disease carries substantially worse outcomes and requires multidisciplinary evaluation.
For individuals with hereditary PDAC predisposition, a peptide vaccine targeting 6 common KRAS mutations generated durable T-cell responses.